Sequential delivery of eosinophil cationic protein and interleukin-4 enhances their therapeutic efficacy for myocardial infarction
Eosinophils protect heart from post-myocardial infarction (MI) injury via cationic protein (ECP) and interleukin-4 (IL-4). Here we engineered and optimized a cell-free therapy for MI via regulated delivery of ECP and IL-4. Pluronic F127 thermosensitive hydrogels embedded with gelatin methacryloyl microspheres (GMs) were constructed for sequential ECP and IL-4 delivery. Immediately following MI, mice received an intrapericardial injection of therapeutic formulations. At 3 days post-MI, codelivery of ECP and IL-4 limited infarct size and preserved cardiac function. Rapid ECP release followed by sustained IL-4 release (IL-4@GM + ECP) yielded the most favorable outcomes with attenuated cardiomyocyte apoptosis and enhanced M2 macrophage contents in post-MI hearts. At 28 days post-MI, IL-4@GM + ECP exhibited robust cardiac functional recovery and cardiac geometry maintenance with minimal fibrotic scarring. Microfil perfusion imaging revealed that IL-4@GM + ECP enhanced angiogenesis with abundant perfused neovessels in the infarcts. Matrigel plug assays confirmed that codelivery of ECP and IL-4 yielded mature and tight vessel structures with CD31 + endothelial cell (EC) lumens surrounded by α-SMA + smooth muscle cells (SMCs) and PDGFR-β + pericytes. Mechanistic studies demonstrated that ECP induced angiogenesis by enhancing EC proliferation, migration, and cellular junctions. Conversely, IL-4 disrupted endothelial junctions but enhanced SMC migration to stabilize nascent endothelium. Sequential delivery of ECP and IL-4 helps generate functional neovessels. The therapeutic efficacy of IL-4@GM + ECP in MI was validated in eosinophil-deficient ΔdblGATA mice. In summary, rapid ECP release, followed by sustained IL-4 release effectively improved cardiac function post-MI by orchestrating neovessel formation, providing a cell-free alternative to eosinophil-based cell therapy for MI.
Authors
- Guangbo Ji (ORCID: https://orcid.org/0009-0000-7079-8896)
- Qiang Zhao (ORCID: https://orcid.org/0000-0003-4656-6002)
- Yushu Chu (ORCID: https://orcid.org/0009-0004-8637-9652)
- Guo-Ping Shi
- Zhixin Xu (ORCID: https://orcid.org/0000-0002-3294-268X)
- Jia Li (ORCID: https://orcid.org/0000-0003-3152-3253)
- 吳亭恩
- Guoxiang Zhao
- Junli Guo
- Meng Qian
- Jinwei Tian
- Yan Chen
- Tongyao Li
- Yamin Zhang
- Yating Mu
Institutions
- Harbin Medical University (CN)
- Peking University (CN)
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- State Key Laboratory of Medicinal Chemical Biology (CN)
- Tianjin Medical University (CN)
- Southeast University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Bioactive Materials
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.bioactmat.2026.08.054
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Natural Science Foundation of Tianjin City